摘要
目的探讨不同药物治疗精神分裂症所产生的经济效果。方法对本院过去2年因精神分裂症住院患者的7种药物治疗方案进行前瞻性研究,筛选出的700例病例根据治疗方案不同随机分为7组:①氯丙嗪组、②舒必利组、③氯氮平组、④利培酮组、⑤奥氮平组、⑥奎硫平组、⑦阿立哌唑组。运用药物经济学成本-效果分析方法进行比较。结果各方案治疗精神分裂症成本分别为17877.61、15526.15、18210.29、13172.20、13950.49、13204.52和13312.75元;每获得一个单位的效果,7种方案所需花费的成本分别为251.79、204.29、200.11、156.81、170.12、165.05和170.67元。结论利培酮、奥氮平、奎硫平和阿立哌唑等新型精神病药似更适合于分裂症治疗。
Objective To discuss the economic effects of different therapeutic schemes in the treatment of schizophrenia Methods 700 cases of schizophrenia were collected from the case history in the past 2 years and were divided randomly into seven groups： compound of chlorpromazine was given to Group （1）, sulpiride was given to group（2）, clozapine was given to Group （3）, risperidone was given to Group （4）, olazapine was given to Group （5）, quetiapine was given to Group （1）6 and aripi- prazole was given to group （7）. The effect and costs of 7 therapies were compared and anal yzed with the pharmacoeconomic cost- effectiveness analysis. Results The costs of seven groups were 17877. 61 Yuan, 15526. 15 Yuan, 18210. 29 Yuan, 13172. 20 Yuan, 13950. 49 Yuan, 13204. 52 Yuan and 13312. 75 Yuan. The result shows that whenever the effective rate in- crease by 1% , the costs of 7 groups also increase 251.79 Yuan, 204. 29 Yuan, 200. 11 Yuan, 156. 81 Yuan, 170. 12 Yuan, 165.05 Yuan and 170. 67 Yuan. Conclusion It suggest that the atypical antipsychotics could treat schizophrenic patients with much lower costs.
出处
《广州医药》
2010年第2期1-4,共4页
Guangzhou Medical Journal
基金
广州市医药卫生科技项目(2007-YB-226)
